MedTrace Logo

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

NCT04827719 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-05-18

No results posted yet for this study

Summary

To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy

Conditions

Interventions

DRUG

BST-236

Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)

Sponsors & Collaborators

  • Groupe Francophone des Myelodysplasies

    lead OTHER

Principal Investigators

  • Marie Anne HOSPITAL, MD · Institut Paoli Calmettes, Marseille

  • PIERRE FENAUX, Pr · Hôpital St Louis-Paris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2025-01-13
Completion
2025-01-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827719 on ClinicalTrials.gov